Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
2002 2
2003 2
2004 2
2005 1
2006 4
2007 5
2008 10
2009 9
2010 18
2011 22
2012 20
2013 30
2014 32
2015 35
2016 28
2017 49
2018 34
2019 64
2020 45
2021 55
2022 83
2023 76
2024 36

Text availability

Article attribute

Article type

Publication date

Search Results

596 results

Results by year

Filters applied: . Clear all
Page 1
Genetic and Phenotype Analysis of a Chinese Cohort of Infants and Children With Epilepsy.
Chuan Z, Ruikun C, Qian L, Shiyue M, Shengju H, Yong Y, Haibo L, Neng X, Yong Z, Huiqin X, Weijia W, Ling H, Bingbo Z, Zhang Q, Yan W, Zongfu C, Xu M. Chuan Z, et al. Among authors: yong y. Front Genet. 2022 Apr 27;13:869210. doi: 10.3389/fgene.2022.869210. eCollection 2022. Front Genet. 2022. PMID: 35571021 Free PMC article.
Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).
Xia L, Mei J, Kang R, Deng S, Chen Y, Yang Y, Feng G, Deng Y, Gan F, Lin Y, Pu Q, Ma L, Lin F, Yuan Y, Hu Y, Guo C, Liao H, Liu C, Zhu Y, Wang W, Liu Z, Xu Y, Li K, Li C, Li Q, He J, Chen W, Zhang X, Kou Y, Wang Y, Wu Z, Che G, Chen L, Liu L. Xia L, et al. Among authors: yuan y. Clin Cancer Res. 2022 Aug 2;28(15):3308-3317. doi: 10.1158/1078-0432.CCR-21-3044. Clin Cancer Res. 2022. PMID: 34844976
Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis.
O'Byrne K, Popoff E, Badin F, Lee A, Yuan Y, Lozano-Ortega G, Eccles LJ, Varol N, Waser N, Penrod JR, Goring S. O'Byrne K, et al. Among authors: yuan y. Lung Cancer. 2023 Mar;177:11-20. doi: 10.1016/j.lungcan.2023.01.006. Epub 2023 Jan 11. Lung Cancer. 2023. PMID: 36669321 Free article.
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
Carbone DP, Ciuleanu TE, Schenker M, Cobo M, Bordenave S, Juan-Vidal O, Menezes J, Reinmuth N, Richardet E, Cheng Y, Mizutani H, Felip E, Zurawski B, Alexandru A, Paz-Ares L, Lu S, John T, Zhang X, Mahmood J, Hu N, De T, Santi I, Penrod JR, Yuan Y, Lee A, Reck M. Carbone DP, et al. Among authors: yuan y. J Immunother Cancer. 2024 Feb 12;12(2):e008189. doi: 10.1136/jitc-2023-008189. J Immunother Cancer. 2024. PMID: 38346853 Free PMC article. Clinical Trial.
596 results